This page provides a timely snapshot of our most recent negotiation activity, including an overview of open files and updates on key milestones from the past 4 weeks.
How current is this information?
The content on this page is updated on an ongoing basis to reflect the most recent available information. Please note that updates about negotiation activity may take 1–2 weeks to be processed.
“Under consideration for negotiation” means we’re currently considering the evidence and gathering other information to inform the negotiation approach, including the drug’s eligibility for expedited negotiation pathways. Once negotiation activities are underway, the drug is in active negotiation.
Letters of engagement
We send letters of engagement (LOE) to manufacturers at the end of the consideration phase, to begin active negotiations. The drugs listed below have recently entered active negotiation.
| Brand name | Manufacturer | Indication | Engagement Date |
|---|---|---|---|
| Dupixent | Sanofi Genzyme Canada | Indicated as an add-on maintenance treatment in adult patients with chronic obstructive pulmonary disease (COPD) characterized by raised blood eosinophils inadequately controlled by the combination of an inhaled corticosteroid (ICS), a long-acting beta2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA), or on a combination of a LABA and a LAMA if ICS is not appropriate. | |
| Tecentriq | Hoffmann-La Roche Ltd. | For the first-line treatment of patients with metastatic NSCLC whose tumours have high PD-L1 expression (PD-L1 stained greater than or equal to 50% of TCs or PD-L1 stained tumour-infiltrating immune cells [ICs] covering greater than or equal to 10% of the tumour area), as determined by a validated test and who do not have EGFR or ALK genomic tumour aberrations. | |
| Blenrep (belantamab mafodotin) | GlaxoSmithKline Inc. | For the treatment of multiple myeloma in combination with pomalidomide and dexamethasone (Bpd) in adult patients who have received at least one prior therapy including lenalidomide. | |
| Blenrep (belantamab mafodotin) | GlaxoSmithKline Inc. | For the treatment of multiple myeloma in combination with bortezomib and dexamethasone (BVd) in adult patients who have received at least one prior therapy. | |
| Conexxence | Fresenius Kabi Canada Ltd. | treatment of postmenopausal women with osteoporosis at high risk for fracture; treatment to increase bone mass in men with osteoporosis at high risk for fracture; treatment to increase bone mass in men with nonmetastatic prostate cancer receiving androgen deprivation therapy, who are at high risk for fracture; treatment to increase bone mass in women receiving adjuvant aromatase inhibitor therapy for nonmetastatic breast cancer; and treatment to increase bone mass for the treatment and prevention of glucocorticoid- induced osteoporosis in women and men at high risk for fracture | |
| Bomyntra | Fresenius Kabi Canada Ltd. | reducing the risk of developing skeletal-related events in patients with multiple myeloma and in patients with bone metastases from breast cancer, prostate cancer, non-small cell lung cancer, and other solid tumors; treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severemorbidity; and treatment of hypercalcemia of malignancy that is refractory to intravenous bisphosphonate | |
| Quillivant ER | KYE Pharmaceuticals Inc. | Attention-deficit/hyperactivity disorder (ADHD) | |
| Yondelis | in combination with doxorubicin as first-line treatment for advanced unresectable |
Letters of intent
A letter of intent (LOI) outlines the negotiated terms of an agreement between the pCPA and a manufacturer at the end of a successful negotiation. The list below reflects our latest LOIs.
| Title | Manufacturer | Indication | Engagement Date | Close Date |
|---|---|---|---|---|
| Scemblix | Novartis Pharmaceuticals Canada Inc. | Adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase | ||
| Imfinzi | AstraZeneca Canada Inc. | In combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy as neoadjuvant and adjuvant treatment, followed by adjuvant durvalumab monotherapy, for the treatment of adult patients with resectable gastric or gastroesophageal junction adenocarcinoma (GC/GEJC). | ||
| Okedi | Bausch Health, Canada Inc. | Schizophrenia in Adults | ||
| Vanflyta | Daiichi Sankyo Pharma Canada | In combination with standard cytarabineand anthracycline induction and standard cytarabine consolidationchemotherapy, and as continuation maintenance monotherapy followingconsolidation, for the treatment of adult patients with newly diagnosed acutemyeloid leukemia (AML) that is FMS-like tyrosine kinase 3 internal tandemduplication (FLT3-ITD) positive. |
Negotiations ended without agreement
Both negotiating parties strive to reach timely agreements. In rare cases, alignment between manufacturers and the pCPA can’t be reached. Each negotiation is unique, and decisions are made based on the information available at the time.
The pCPA always welcomes unsolicited offers, should a manufacturer want to re-engage and go back to the negotiation table.
When agreements can’t be reached, public drug plans may make decisions about providing coverage through their exceptional access programs.
| Title | Manufacturer | Indication | Engagement Date | Close Date |
|---|---|---|---|---|
| Opzelura | Incyte Biosciences Canada Corporation | Atopic dermatitis | ||
| Elahere | AbbVie Corporation | For the treatment of adult patients with folate receptor-alpha (FRα) positive*, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. |
Negotiations that weren’t pursued - Last 4 weeks
We don’t pursue negotiations in cases where the drug’s health technology assessment (HTA) recommendations were negative or “do not reimburse.” Other reasons, such as the manufacturer declining to negotiate or a lack of supply of the drug in Canada, may be reflected on the drug’s page in the database.
| Title | Manufacturer | Indication | Close Date |
|---|---|---|---|
| Loqtorzi | Apotex Inc. | for the treatment of adults with recurrent unresectable or metastatic nasopharyngeal carcinoma (NPC) with disease progression on or after a platinum-containing chemotherapy |